Claus Torp Jensen Has Been Appointed First Chief Digital Officer and Head of Technology for Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center (MSK) today announced that Claus Torp Jensen, PhD, has joined the institution as its first Chief Digital Officer and Head of Technology. His recruitment follows an expansive national search to identify a leader...
14-Oct-2019 10:00 AM EDT Add to Favorites

New Study Examines Wilms’ Tumor Relapse and May Give Clues to about Which Other Childhood Cancers Could Relapse

Today, researchers from MSK Kids at Memorial Sloan Kettering Cancer Center (MSK) published results that examine elevated levels of a protein called prohibitin in the urine and tumors of children with Wilms’ tumors. Their findings could help...
8-Aug-2019 9:05 AM EDT Add to Favorites

Memorial Sloan Kettering Among the Top “Best Hospitals” for Cancer Care and Ranked First in Gynecology by U.S News & World Report

Memorial Sloan Kettering Cancer Center (MSK) has been ranked as the number two hospital for cancer care in the nation, according to U.S. News & World Report in its annual listing of Best Hospitals. Since the inception of the rankings 30 years ago,...
30-Jul-2019 10:05 AM EDT Add to Favorites

Cracking a Code: Landmark Prospective Study Helps Researchers Better Understand Which MGUS Patients Will Progress to a Multiple Myeloma Diagnosis

Memorial Sloan Kettering Cancer Center (MSK) researchers published new results that found that individuals with low-risk or intermediate-risk myeloma precursor disease known as monoclonal gammopathy of undetermined significance (MGUS) can convert to...
18-Jul-2019 11:05 AM EDT Add to Favorites

MSK-ACCESS Receives New York State Approval for New Molecular Assay

Memorial Sloan Kettering Cancer Center (MSK) announced that the New York State Department of Health has issued an approval for a new molecular assay called Analysis of Circulating cfDNA to Evaluate Somatic Status (MSK-ACCESS).
21-Jun-2019 3:00 PM EDT Add to Favorites

Following Milestone FDA Approval, MSK Researchers Address Resistance to Larotrectinib through Next-Generation TRK-Targeted Therapeutic

LOXO-195, a next-generation TRK inhibitor also known as BAY 2731954, has shown signs of clinical activity in individuals with NTRK gene fusion-positive solid tumors that have become resistant to first-generation TRK inhibitors. Results from a phase...
1-Apr-2019 4:05 PM EDT Add to Favorites

MSK Researchers Identify a New Method to “Genetically Cloak” Cancer-Fighting Immune Cells

During cancer immunotherapy, immune cells often undergo a form of cellular suicide, termed apoptosis, which can limit the therapy’s effectiveness.
29-Jan-2019 12:05 PM EST Add to Favorites

New Study Reveals Gut Microbes May Help Protect People Having a Bone Marrow Transplant

Researchers at Memorial Sloan Kettering Cancer Center (MSK) reported results from a new study that looks at the likelihood of complications for people undergoing bone marrow transplants (BMTs). The observational study found that people with lower...
3-Dec-2018 10:05 AM EST Add to Favorites

see all news